Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Pre-Registration for Prostate Cancer. According to GlobalData, Pre-Registration drugs for Prostate Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Docetaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Docetaxel overview
Docetaxel (Beizray) is a semi-synthetic, second-generation taxane, that acts as antineoplastic agent. It is formulated as solution for injection for intravenous route of administration. Beizray is indicated for the treatment of Breast cancer single agent for locally advanced or metastatic bc after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive bc, non-small cell lung cancer single agent for locally advanced or metastatic nsclc after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated nsclc, castration-resistant prostate cancer with prednisone in metastatic castration-resistant prostate cancer, gastric adenocarcinoma with cisplatin and fluorouracil for untreated, advanced gc, including the gastroesophageal junction, and squamous cell carcinoma of the head and neck with cisplatin and fluorouracil for induction treatment of locally advanced Squamous cell carcinoma of head and neck (SCCHN).
Docetaxel (BH009) is under development for the treatment of solid tumors, head and neck squamous cell carcinoma (including oropharynx, oral cavity, hypopharynx, and larynx and ovarian cancer (including epithelial ovarian carcinoma, fallopian tube carcinoma, and primary peritoneal carcinoma). It is administered through intravenous route. The drug candidate acts by targeting tubulin.
The drug candidate is under development for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer and triple negative breast cancer.
Zhuhai Beihai Biotech overview
Zhuhai Beihai Biotech is a pharmaceutical company that dedicated to the development of innovative tumor drugs with unmet clinical needs. The company is headquartered in China.
For a complete picture of Docetaxel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
